« Return to News | R&D Trends

Mount Sinai, Exosome Diagnostics partner

Friday, August 30, 2013 02:29 PM

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics are collaborating on the R&D of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The five-year agreement will allow the companies to establish targeted research and biomarker discovery programs in oncology and inflammation. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

Carlos Cordon-Cardo, M.D., Ph.D., chair, department of pathology, Icahn School of Medicine at Mount Sinai, said, "Biofluid-based, point-in-time analyses will lead to an improved, patient-centric understanding of disease, thereby guiding more informed treatment decisions and response to therapy."

The agreement was negotiated by Mount Sinai Innovation Partners, which encourages the commercialization of novel research conducted at the Icahn School of Medicine. Mount Sinai plans to leverage the experience of its clinical investigators in areas of unmet medical needs to develop clinical study programs taking advantage of Exosome's technology that has the ability to extract high-quality RNA from blood, urine and cerebrospinal fluid.

Mount Sinai will retain rights to molecular biomarkers associated with disease progression and drug response, and Exosome will retain commercial development rights for molecular in vitro diagnostic products.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.